信达生物(01801.HK)阿达木单抗注射液获国家药监局批准两项新适应症
信达生物(01801.HK)公布,公司自主研发的重组人抗肿瘤坏死因子-α单克隆抗体药物苏立信(阿达木单抗注射液)正式获得国家药品监督管理局批准两项新适应症,用於治疗儿童斑块状银屑病;及对糖皮质激素应答不充分、需要节制使用糖皮质激素、或不适合进行糖皮质激素治疗的成年非感染性中间葡萄膜炎、後葡萄膜炎和全葡萄膜炎。
集团指,苏立信於今年9月2日首次获得国家药品监督管理局上市批准。此前苏立信已获批的适应症包括类风湿关节炎、强直性脊柱炎、银屑病、多关节型幼年特发性关节炎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.